Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Sep 16, 2019 in Prostate cancer | 0 comments

In a nutshell

This study aimed to evaluate the safety and effectiveness of radium-223 (Xofigo, formerly known as Alpharadin) in patients with advanced prostate cancer that has spread to the bones and who have had this treatment previously. This study found that re-treatment with radium-223 was well tolerated and with good results.

Some background

Radium-223 is a treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC). CRPC is a form of prostate cancer where the cancer cannot be controlled by hormone therapy. This treatment involves 6 injections. It is a type of internal radiotherapy.  

The safety and effectiveness of re-treatment with radium-223 in patients with mCRPC spread to the bone are unknown.

Methods & findings

This study included 34 patients. These patients had had radium-223 treatment previously. Re-treatment was done after 6 months from the first 6 injections. Chemotherapy was not taken during the course of treatment. They were followed up for 2 years.

No serious drug-related side effects were noted. 12% of patients reported severe side effects such as joint pain, spine compression, or muscle weakness. No new cancers were reported during the 2-year follow-up period.

Death or cancer progression occurred in 43% of the patients. Progression of cancer in the bone occurred in 11% of patients. The average overall survival was 24.4 months. The estimated 2-year overall survival rate was 50%.

The bottom line

This study found that re-treatment with radium-223 was well tolerated in patients with mCRPC spread to the bone.

The fine print

This study had a very small number of participants and a short follow-up period. Larger studies are needed. Also, there was no comparison group. This study was funded by Bayer, the manufacturer of radium-223.

Published By :


Date :

Aug 23, 2019

Original Title :

Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.

click here to get personalized updates